Source comparison
DAC vs No-DAC: Why This Isn't a Minor Detail
CJC-1295 without DAC (Mod GRF 1-29) and CJC-1295 with DAC are not dose-equivalent compounds. The DAC modification. A maleimido-propionic acid linker that covalently binds to circulating albumin. Extends the peptide's elimination half-life from 30 minutes to ap
This comparison does not assign a generated winner or score.
- CJC-1295 without DAC (Mod GRF 1-29) and CJC-1295 with DAC are not dose-equivalent compounds. The DAC modification. A maleimido-propionic acid linker that covalently binds to circulating albumin. Extends the peptide's elimination half-life from 30 minutes to approximately 6–8 days. That 200-fold difference in clearance rate fundamentally changes how the compound should be dosed, how frequently it should be administered, and what type of GH secretion pattern it produces.
- Researchers treating these as interchangeable face predictable failures. CJC-1295 without DAC requires multiple daily dosing (typically 100–200 mcg three times daily) to maintain therapeutic GH elevation because the peptide clears within 2–3 hours. CJC-1295 with DAC can be dosed once weekly at 500–1000 mcg because albumin binding creates a sustained-release effect. Using a no-DAC protocol with a DAC-modified peptide results in supraphysiological GH exposure that skews pharmacodynamic endpoints. Using a DAC protocol with a no-DAC peptide results in subtherapeutic exposure between doses.
- This CJC-1295 myths cost money health error is entirely preventable. But only if procurement teams verify which molecular form they're receiving. Suppliers sometimes list 'CJC-1295' without specifying DAC status, and researchers assume the cheaper option is equivalent. It's not. CJC1295 Ipamorelin 5MG 5MG formulations must explicitly state which variant is included. Ambiguity on this point is a red flag for supplier quality control.